31 Jan 25
Welcome to tranScrip’s monthly newsletter where we share with you the latest news and views from across the organisation.
This edition includes:
A Message from our Chief Executive Officer
Dear Readers,
Happy New Year to you all. As we start the new year we are looking forward to the opportunities and undoubtedly the challenges that lie ahead. We are looking forward to a year of further growth and innovation and we are looking forward to working together as a tranScrip team to support our clients in helping to expedite the development and commercialisation of their products for the benefit of patients worldwide.
Together, we will continue to navigate the complexities of the healthcare landscape, leveraging our expertise to drive success in your projects and deliver meaningful outcomes for patients.
Thank you for your trust in tranScrip. Here’s to a year of progress, collaboration, and shared success.
Warm regards, Mark Corbett, CEO, tranScrip
Welcoming our New Joiners
tranScrip is delighted to announce the appointment of Rob Fox as Chief Commercial Officer.
Rob brings over two decades of expertise in pharmaceutical services, specialising in commercial leadership, strategic development, and corporate growth.
His career spans over 20 years of commercial functions, working across therapeutic areas including oncology, CNS, infectious disease, immunology, and rare disease therapies.
Rob is recognised for his collaborative approach, partnering closely with clinical, medical, and commercial teams to ensure patients with unmet medical needs have access to transformative medicines. He has worked with over 15 of the top 20 global pharmaceutical companies and numerous mid-sized and emerging biotech firms, driving M&A activities, service expansions, and supporting clients throughout pre- and post-launch phases.
Be a Part of Our Success Story – Join the tranScrip Team
At tranScrip, we’re driven by passion, innovation, and excellence. We are searching for talented professionals ready to make a meaningful impact in the world of healthcare and life sciences. If you’re seeking a career where your expertise will make a difference, we’d love to hear from you.
View our current vacancies here > https://transcrip-group.com/careers/vacancies/
JPM Week Highlights: Insights from San Francisco
This month, Mark Corbett, Rob Fox, and Flic Gabbay represented tranScrip at JPM Week in what was luckily a sunny San Francisco. Once again it was a vibrant gathering that involved industry leaders and innovators from around the globe and was filled with insightful discussions, emerging trends, and networking opportunities that underscore the dynamic nature of our field.
One of the highlights was the announcement of one sizeable M&A deal in the form of Johnson & Johnson’s $14.6Bn acquisition of Intra-Cellular which is good news given there was a lack of large acquisitions in 2024. We also saw other new smaller deals such as GSK’s acquisition of IDRx for $1.15Bn and Lilly acquiring Scorpion Therapeutics’ P13Kα pipeline for $2.5Bn. Hopefully it is a sign of a start to a buoyant year across healthcare in 2025.
Another prominent topic of conversation was the potential global impact of Donald Trump’s presidency on the biotech industry, both in the US and further afield, including the UK. Certainly there seems to be differing opinions on what impact it will have so we will be watching closely because any disruptions in US-UK trade or regulatory alignment might challenge access to key biotech markets, particularly given the US’s leadership as a biotech innovator and investor.
There was heavy attendance at the conference from Chinese biotech with a number of forums focusing on this area. Again, this is perhaps no surprise given the innovation coming out of China and may well present new opportunities for companies like tranScrip who can support these biotech’s break into western markets.
And lastly, another theme at the conference was technology, and we are not just talking about the driverless cars zipping up and down the streets of the city. There was a continued running theme around AI but also around tech-enabled services that support clinical trials, commercialisation and supply chain. This is clearly a theme we anticipate to feature more heavily on the agenda in future years.
Lights, Camera, Action! Behind the Scenes at tranScrip
We’ve had an exciting few days in the office, filming content and capturing interviews with our team. It’s been a great opportunity to showcase the passion, expertise, and innovation that drives tranScrip every day.
From insightful discussions to behind-the-scenes moments, we’re excited to bring you a glimpse into the people and ideas shaping our work. We’re looking forward to sharing our work with you—stay tuned!
Upcoming Conferences and Events
Rienk Pypstra will play an important role at BEAM Alliance‘s AMR Conference, a global gathering addressing the critical challenges of antimicrobial resistance.
On Wednesday 26th February, Rienk will moderate an engaging panel discussion titled “Clinical Endpoints: Fit-for-Purpose?”. This session will delve into the current landscape and future requirements of clinical endpoints in antimicrobial development, featuring valuable insights from renowned experts in the field:
Inigo Montes will also be joining Rienk at the conference so please reach out to us to explore new opportunities, discuss potential partnerships, or simply catch up > Contact Us
Thank you for reading this month’s edition of tranScrip’s newsletter. Feel free to share your feedback in the comments.
To learn more about tranScrip’s services and how we can support you, connect with us.
Best regards, The tranScrip Team
Our experienced physicians and scientists, together with our regulatory, clinical and commercial experts can support you to maximise the value of your products. Whatever your project requires, we have the expertise to meet your needs.
